文献速递血栓与止血

定制频率递增式初级预防用于重型A型血友病:加拿大血友病预防研究16年纵向队列结果

Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort.
PubMed 文献 · Lancet Haematol · 2018-05-03

加拿大12中心56例重型A型血友病男童1.0-2.5岁入组,接受标准半衰期重组凝血因子VIII,从每周一次50 IU/kg起始,按方案根据突破性出血递增频率。中位随访10.2年,中位年化索引关节出血率0.95次/年,末次改良CCPES踝关节中位评分为1,无治疗相关安全事件,17例(30%)曾出现方案定义不可接受的突破性出血。

要点

  • 从每周一次50 IU/kg起始,按方案根据突破性出血递增频率并调整剂量。
  • 中位随访10.2年,中位年化索引关节出血率0.95次/年(IQR 0.44-1.35)。
  • 末次左踝CCPES中位评分1(IQR 1-3),右踝1(IQR 1-2),其余关节中位0。

核心结论

  • 定制频率递增式预防可导致极少关节病,在WHO-ICF领域内健康结局很好,且与标准预防方案相比仅使用中等量昂贵凝血因子。
  • 队列中观察到一些出血后遗症,作者认为未来研究应考虑更严格的递增方案。

研究设计与样本

  • 纵向研究,纳入加拿大12个中心的56例重型A型血友病男童,入组年龄1.0-2.5岁。
  • 治疗方案为标准半衰期重组凝血因子VIII(SHL-rFVIII),从每周一次50 IU/kg预防开始,按方案根据突破性出血递增频率并伴随剂量调整。
  • 主要终点为研究结束时改良Colorado儿童体格检查评分(CCPES)测量的关节健康,所有分析按意向治疗进行。
  • 研究已完成,在ClinicalTrials.gov注册,编号NCT01085344。

主要发现

  • 1997年6月26日至2007年1月30日入组56例男童,中位随访10.2年(最长16.1年)。
  • 中位rFVIII用量约3600 IU/kg/年。
  • 研究结束时左踝CCPES体格检查评分中位1(IQR 1-3;范围0-12),右踝中位1(IQR 1-2;范围0-12),所有其他关节中位评分为0。
  • 研究期间无治疗相关安全事件,包括中心静脉导管感染。
  • 中位年化索引关节出血率为0.95次/年(IQR 0.44-1.35;范围0.00-13.43),但17例(30%)患者在研究期间某一时点出现方案定义不可接受的突破性出血。

局限性

  • 作者指出队列中观察到一些出血后遗症,未来研究应考虑更严格的递增方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe haemophilia A has high morbidity, and treatment, while effective, is very expensive. We report the 16-year follow-up of the Canadian Hemophilia Prophylaxis Study, which examined the effectiveness of tailored frequency-escalated primary prophylaxis with a focus on health outcomes within the domains of body structures and functions, and activities and participation (according to the WHO International Classification of Functioning, Disability and Health [WHO-ICF] framework) and a view to reducing consumption of costly clotting factor, which accounts for more than 90% of the cost of care of severe haemophilia. METHODS: In this longitudinal study, boys with severe haemophilia A from 12 Canadian centres were enrolled at age 1·0-2·5 years. They were treated with standard half-life recombinant factor VIII (SHL-rFVIII), beginning as once-weekly prophylaxis with 50 IU/kg and escalating in frequency (with accompanying dose adjustments) in response to breakthrough bleeding as determined by the protocol. The primary endpoint for this analysis was joint health, as measured by the modified Colorado Child Physical Examination Scores (CCPES) at study end. All analyses were done by intention to treat. The trial is complete, and is registered with ClinicalTrials.gov, number NCT01085344. FINDINGS: Between June 26, 1997, and Jan 30, 2007, 56 boys were enrolled. They were followed for a median of 10·2 years (to a maximum of 16·1 years). Median rFVIII usage was about 3600 IU/kg per year. The median end-of-study CCPES physical examination score was 1 (IQR 1-3; range 0-12) for the left ankle and 1 (1-2; 0-12) for the right ankle, with all other joints having a median score of 0. No treatment-related safety events occurred over the duration of the study, including central venous catheter infections. The median annualised index joint bleeding rate was 0·95 per year (IQR 0·44-1·35; range 0·00-13·43), but 17 (30%) patients had protocol-defined unacceptable breakthrough bleeding at some point during the study. INTERPRETATION: Tailored frequency-escalated prophylaxis leads to very little arthropathy and very good health outcomes within the WHO-ICF domains, and only uses a moderate amount of expensive clotting factor as compared with standard prophylaxis protocols. Some sequelae of bleeding were observed in our cohort, and future studies should consider a more stringent protocol of escalation. FUNDING: This study was initially funded by grants from the Medical Research Council of Canada/Pharmaceutical Manufacturers Association of Canada Partnership Fund and the Bayer/Canadian Blood Services/Hema-Quebec Partnership Fund. Subsequent renewals were funded by Bayer.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Feldman BM, Rivard GE, Babyn P, et al. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. Lancet Haematol. 2018. PMID: 29731369. doi:10.1016/S2352-3026(18)30048-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。